Travere Therapeutics: Still Undervalued Post FSGS Approval (NASDAQ:TVTX)
Summary
Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, peak sales outlook, and key ri...
Description
Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, peak sales outlook, and key ri...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source